José
Palacios Calvo
Profesor/a Titular Universidad
![Foto de José](/img/nophoto.png)
![Foto de Hospital Clínico San Carlos de Madrid](/img/noimage_org.png)
Hospital Clínico San Carlos de Madrid
Madrid, EspañaHospital Clínico San Carlos de Madrid -ko ikertzaileekin lankidetzan egindako argitalpenak (10)
2021
-
LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology
Cancer Medicine, Vol. 10, Núm. 17, pp. 5878-5888
2017
-
18F-fluoromisonidazole PET and activity of neoadjuvant nintedanib in early HER2-negative breast cancer: A window-of-opportunity randomized trial
Clinical Cancer Research, Vol. 23, Núm. 6, pp. 1432-1441
-
Characterisation of the novel deleterious RAD51C p.Arg312Trp variant and prioritisation criteria for functional analysis of RAD51C missense changes
British Journal of Cancer, Vol. 117, Núm. 7, pp. 1048-1062
2016
-
High proliferation predicts pathological complete response to neoadjuvant chemotherapy in early breast cancer
Oncologist, Vol. 21, Núm. 2, pp. 150-155
2013
-
Fe de errores a «Recomendaciones para la determinación de mutaciones de K-RAS en cáncer de colon»
Revista Espanola de Patologia
2012
-
Prospective transGEICAM study of the impact of the 21-gene recurrence score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer
Annals of Oncology, Vol. 23, Núm. 3, pp. 625-631
-
Recomendaciones para la determinación de mutaciones de K-RAS en cáncer de colon
Revista Espanola de Patologia
2009
-
Guidelines for HER2 testing in breast cancer. A national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
Revista Espanola de Patologia, Vol. 42, Núm. 1, pp. 3-16
-
Guidelines for HER2 testing in breast cancer: A national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM)
Clinical and Translational Oncology, Vol. 11, Núm. 6, pp. 363-375
2008
-
Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer
Journal of the National Cancer Institute, Vol. 100, Núm. 11, pp. 805-814